作者
Seval Akpinar, Mehmet Hilmi Dogu, Serhat Celik, Omer Ekinci, Ipek Yonal Hindilerden, Mehmet Sinan Dal, Eren Arslan Davulcu, Atakan Tekinalp, Fehmi Hindilerden, Busra Gokce Ozcan, Tuba Hacibekiroglu, Mehmet Ali Erkurt, Metin Bagci, Sinem Namdaroglu, Gulten Korkmaz, Oktay Bilgir, Gulsum Akgun Cagliyan, Hacer Berna Afacan Ozturk, Istemi Serin, Tarık Onur Tiryaki, Duzgun Ozatli, Serdal Korkmaz, Turgay Ulas, Bulent Eser, Burhan Turgut, Fevzi Altuntas
发表日期
2022/3/1
期刊
Clinical Lymphoma Myeloma and Leukemia
卷号
22
期号
3
页码范围
169-173
出版商
Elsevier
简介
Introduction/Background
The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings.
Patients/Methods
A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers.
Results
The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+/p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were ≥ grade 3 …
学术搜索中的文章
S Akpinar, MH Dogu, S Celik, O Ekinci, IY Hindilerden… - Clinical Lymphoma Myeloma and Leukemia, 2022